TR201806882T4 - Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri. - Google Patents

Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri. Download PDF

Info

Publication number: TR201806882T4
Authority: TR; Turkey
Prior art keywords: phenyl; oxy; compound; thiophen; benzo
Prior art date: 2013-02-19

Application number

TR2018/06882T

Other languages

English (en)

Turkish (tr)

Inventor

Elizabeth Burks Heather

A Dechantsreiter Michael

He Guo

Nunez Jill

Peukert Stefan

Springer Clayton

Sun Yingchuan

Marie-France Thomsen Noel

Scott Tria George

Yu Bing

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-19

Filing date

2014-02-12

Publication date

2018-06-21

2014-02-12 Application filed by Novartis Ag filed Critical Novartis Ag

2018-06-21 Publication of TR201806882T4 publication Critical patent/TR201806882T4/tr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

TR2018/06882T 2013-02-19 2014-02-12 Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri. TR201806882T4 (tr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361766439P	2013-02-19	2013-02-19

Publications (1)

Publication Number	Publication Date
TR201806882T4 true TR201806882T4 (tr)	2018-06-21

Family

ID=50239942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR2018/06882T TR201806882T4 (tr)	2013-02-19	2014-02-12	Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri.

Country Status (46)

Country	Link
US (5)	US8877801B2 (fr)
EP (2)	EP3360870A1 (fr)
JP (1)	JP6364028B2 (fr)
KR (1)	KR102279999B1 (fr)
CN (1)	CN105008343B (fr)
AP (1)	AP2015008618A0 (fr)
AR (1)	AR094704A1 (fr)
AU (1)	AU2014219283C1 (fr)
BR (1)	BR112015018882B1 (fr)
CA (1)	CA2899030C (fr)
CL (1)	CL2015002098A1 (fr)
CR (1)	CR20150424A (fr)
CU (1)	CU24337B1 (fr)
CY (1)	CY1120155T1 (fr)
DK (1)	DK2958907T3 (fr)
DO (1)	DOP2015000202A (fr)
EA (1)	EA028032B1 (fr)
ES (1)	ES2671516T3 (fr)
GE (1)	GEP201706638B (fr)
GT (1)	GT201500233A (fr)
HK (1)	HK1251227A1 (fr)
HR (1)	HRP20180816T1 (fr)
HU (1)	HUE039052T2 (fr)
IL (1)	IL240131B (fr)
JO (1)	JO3494B1 (fr)
LT (1)	LT2958907T (fr)
MA (1)	MA38325B1 (fr)
ME (1)	ME03061B (fr)
MX (1)	MX359471B (fr)
MY (1)	MY174888A (fr)
NI (1)	NI201500106A (fr)
NO (1)	NO3077717T3 (fr)
NZ (1)	NZ710385A (fr)
PE (1)	PE20151428A1 (fr)
PH (1)	PH12015501832B1 (fr)
PL (1)	PL2958907T3 (fr)
PT (1)	PT2958907T (fr)
RS (1)	RS57106B1 (fr)
SG (1)	SG11201505697VA (fr)
SI (1)	SI2958907T1 (fr)
TN (1)	TN2015000323A1 (fr)
TR (1)	TR201806882T4 (fr)
TW (1)	TWI612040B (fr)
UY (1)	UY35334A (fr)
WO (1)	WO2014130310A1 (fr)
ZA (1)	ZA201505305B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3360870A1 (fr)	2013-02-19	2018-08-15	Novartis AG	Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des estrogènes
WO2016132998A1 (fr) *	2015-02-19	2016-08-25	Jnc株式会社	Composé cristallin liquide comprenant du benzothiophène, composition de cristaux liquides et élément d'affichage à cristaux liquides
TWI708770B (zh)	2015-06-08	2020-11-01	日商捷恩智股份有限公司	具有苯并噻吩的液晶性化合物、液晶組成物及液晶顯示元件
CA3008020C (fr) *	2015-12-09	2024-02-20	The Board Of Trustees Of The University Of Illinois	Represseurs du recepteur oestrogenique selectifs a base de benzothiophene
IL295050A (en)	2016-04-01	2022-09-01	Recurium Ip Holdings Llc	Estrogen receptor modulators
WO2018081168A2 (fr) *	2016-10-24	2018-05-03	The Board Of Trustees Of The University Of Illinois	Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
IL267795B2 (en) *	2017-01-06	2023-02-01	G1 Therapeutics Inc	Combination therapy for the treatment of cancer
CA3052810A1 (fr)	2017-02-10	2018-08-16	G1 Therapeutics, Inc.	Modulateurs du recepteur des strogenes de benzothiophene
BR112020008888A2 (pt)	2017-11-16	2020-10-20	Novartis Ag	terapias de combinação
WO2019097426A1 (fr)	2017-11-16	2019-05-23	Novartis Ag	Association pharmaceutique comprenant le lsz102 et le ribociclib
WO2019106604A1 (fr)	2017-12-01	2019-06-06	Novartis Ag	Combinaison pharmaceutique comprenant du lsz102 et de l'alpésilib
CN119161384A (zh) *	2018-01-22	2024-12-20	雷迪厄斯制药公司	雌激素受体调节化合物
US11759450B2 (en)	2018-02-06	2023-09-19	The Board Of Trustees Of The University Of Illinois	Substituted benzothiophene analogs as selective estrogen receptor degraders
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019321677A1 (en) *	2018-08-16	2021-03-11	G1 Therapeutics, Inc.	Benzothiophene estrogen receptor modulators to treat medical disorders
AU2019402189B2 (en)	2018-12-20	2023-04-13	Novartis Ag	Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015672A2 (pt)	2019-02-15	2021-10-05	Novartis Ag	Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
US20220144807A1 (en)	2019-02-15	2022-05-12	Novartis Ag	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3972651A2 (fr)	2019-05-20	2022-03-30	Novartis AG	Conjugués anticorps-médicament inhibiteurs de mcl-1 et procédés d'utilisation
CA3148221A1 (fr)	2019-08-06	2021-02-11	Recurium Ip Holdings, Llc	Modulateurs de recepteur d'strogenes pour le traitement de mutants
EP4076660A1 (fr)	2019-12-20	2022-10-26	Novartis AG	Utilisations d'anticorps anti-tgf-bêtas et inhibiteurs de point de contrôle pour le traitement des maladies prolifératives
CN111057065B (zh) *	2019-12-24	2021-04-23	沈阳药科大学	噻吩并嘧啶类化合物的制备方法和用途
CN111646972B (zh) *	2020-06-12	2021-06-29	上海皓元医药股份有限公司	一种选择性雌激素受体降解剂及其中间体的制备方法
JP2023531676A (ja)	2020-06-23	2023-07-25	ノバルティスアーゲー	３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
TW202216676A (zh) *	2020-07-06	2022-05-01	美商塔朵根公司	用於心理疾病或心理強化的有益苯并噻吩組合物
US20230271940A1 (en)	2020-08-03	2023-08-31	Novartis Ag	Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20240042051A1 (en)	2020-11-24	2024-02-08	Francesca Rocchetti	Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4251648A2 (fr)	2020-11-24	2023-10-04	Novartis AG	Anticorps anti-cd48, conjugués anticorps-médicament et leurs utilisations
EP4267578A4 (fr)	2020-12-23	2024-11-20	Recurium IP Holdings, LLC	Modulateurs du récepteur des éstrogènes
CN117794929A (zh)	2021-02-02	2024-03-29	法国施维雅药厂	选择性bcl-xl protac化合物及使用方法
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
CN116265458A (zh) *	2021-12-17	2023-06-20	中国科学院上海药物研究所	苯并噻吩类衍生物、及其制备方法和用途
GB2617173B (en)	2022-03-31	2024-11-20	Iceye Oy	Detecting and suppressing ambiguities in synthetic aperture radar data and images
CA3256012A1 (fr)	2022-05-20	2023-11-23	Les Laboratoires Servier	Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
EP4525925A1 (fr)	2022-05-20	2025-03-26	Novartis AG	Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées
CN115710248B (zh) *	2022-11-18	2024-06-21	南京中医药大学	新型选择性雌激素受体下调剂化合物、制备方法及用途
KR20250160354A (ko)	2023-03-10	2025-11-12	노파르티스 아게	Panras 억제제 항체-약물 콘쥬게이트 및 이의 사용 방법
WO2025111450A1 (fr)	2023-11-22	2025-05-30	Les Laboratoires Servier	Conjugués anticorps anti-cd74-médicament et leurs procédés d'utilisation
WO2025215536A1 (fr)	2024-04-10	2025-10-16	Novartis Ag	Inhibiteurs de panras macrocycliques pour le traitement du cancer

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH445129A (fr)	1964-04-29	1967-10-15	Nestle Sa	Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3426011A (en)	1967-02-13	1969-02-04	Corn Products Co	Cyclodextrins with anionic properties
US3453257A (en)	1967-02-13	1969-07-01	Corn Products Co	Cyclodextrin with cationic properties
US3453259A (en)	1967-03-22	1969-07-01	Corn Products Co	Cyclodextrin polyol ethers and their oxidation products
JPS6041077B2 (ja)	1976-09-06	1985-09-13	喜徳喜谷	１，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4261989A (en)	1979-02-19	1981-04-14	Kaken Chemical Co. Ltd.	Geldanamycin derivatives and antitumor drug
ZA822247B (en) *	1981-04-03	1983-11-30	Lilly Co Eli	Benzothiophene compounds and process for preparing them
US4418068A (en)	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US5266573A (en)	1989-08-07	1993-11-30	Elf Sanofi	Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0647450A1 (fr)	1993-09-09	1995-04-12	BEHRINGWERKE Aktiengesellschaft	Prodrogues améliorées pour activation médiée par enzyme
US6756388B1 (en)	1993-10-12	2004-06-29	Pfizer Inc.	Benzothiophenes and related compounds as estrogen agonists
US6562862B1 (en) *	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
IL115849A0 (en)	1994-11-03	1996-01-31	Merz & Co Gmbh & Co	Tangential filtration preparation of liposomal drugs and liposome product thereof
US5589482A (en)	1994-12-14	1996-12-31	Pfizer Inc.	Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5998441A (en)	1995-02-28	1999-12-07	Eli Lilly And Company	Benzothiophene compounds, intermediates, compositions, and methods
US5510357A (en)	1995-02-28	1996-04-23	Eli Lilly And Company	Benzothiophene compounds as anti-estrogenic agents
ES2163587T3 (es) *	1995-02-28	2002-02-01	Lilly Co Eli	Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos.
US6417199B1 (en)	1995-03-10	2002-07-09	Eli Lilly And Company	3-benzyl-benzothiophenes
ATE198477T1 (de) *	1995-06-26	2001-01-15	Lilly Co Eli	Benzothiophenderivate
US5731342A (en)	1996-02-22	1998-03-24	Eli Lilly And Company	Benzothiophenes, formulations containing same, and methods
US5827876A (en) *	1996-04-09	1998-10-27	American Home Products Corporation	Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
US5886025A (en)	1997-03-06	1999-03-23	Baylor University	Anti-mitotic agents which inhibit tubulin polymerization
ZA982819B (en)	1997-04-09	1999-10-04	Lilly Co Eli	Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA982877B (en)	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.
ZA982818B (en)	1997-04-09	1999-10-04	Lilly Co Eli	Prevention of breast cancer using selective estrogen receptor modulators.
US6166069A (en)	1998-05-12	2000-12-26	American Home Products Corporation	Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
CA2331120A1 (fr)	1998-05-12	1999-11-18	Iwan Gunawan	Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en)	2000-08-01	2000-09-20	Novartis Ag	Organic compounds
CA2402315A1 (fr)	2000-03-09	2001-09-13	Michael Jaye	Utilisations therapeutiques des mediateurs ppar
US7091240B2 (en)	2000-03-10	2006-08-15	Oxigene, Inc.	Tubulin binding ligands and corresponding prodrug constructs
US6995162B2 (en)	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US7425565B2 (en)	2002-05-09	2008-09-16	Cedars-Sinai Medical Center	Use of benzothiopenes to treat and prevent prostate cancer
JP4547911B2 (ja)	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
PL215865B1 (pl)	2002-03-05	2014-02-28	Axys Pharmaceuticals	Zwiazek, kompozycja farmaceutyczna i zastosowanie zwiazku
TWI275390B (en)	2002-04-30	2007-03-11	Wyeth Corp	Process for the preparation of 7-substituted-3- quinolinecarbonitriles
PL374845A1 (en)	2002-07-22	2005-11-14	Eli Lilly And Company	Selective estrogen receptor modulators containing a phenylsulfonyl group
ATE407129T1 (de)	2003-06-10	2008-09-15	Lilly Co Eli	Pentafluoroalkylsulfin-naphthaline und und darauf bezogene modulatoren des östrogenrezeptors
US7399865B2 (en)	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
ATE448215T1 (de)	2004-01-22	2009-11-15	Lilly Co Eli	Selektive östrogen-rezeptor-modulatoren
WO2005073205A1 (fr)	2004-01-22	2005-08-11	Eli Lilly And Company	Modulateurs selectifs du recepteur des oestrogenes
EP1713770A1 (fr)	2004-01-29	2006-10-25	Eli Lilly And Company	Modulateurs selectifs du recepteur des oestrogenes
KR20210090744A (ko)	2004-09-02	2021-07-20	제넨테크, 인크.	헤지호그 신호전달에 대한 피리딜 억제제
US7998974B2 (en)	2005-03-03	2011-08-16	Sirtris Pharmaceuticals, Inc.	Fused heterocyclic compounds and their use as sirtuin modulators
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
AU2008229183A1 (en)	2007-03-16	2008-09-25	Eli Lilly And Company	Process and intermediates for preparing arzoxifene
KR101584823B1 (ko)	2007-09-12	2016-01-22	제넨테크, 인크.	포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
US20090069380A1 (en)	2007-09-12	2009-03-12	Protia, Llc	Deuterium-enriched aroxifene
CN101909631B (zh)	2007-10-25	2012-09-12	健泰科生物技术公司	制备噻吩并嘧啶化合物的方法
US8168784B2 (en)	2008-06-20	2012-05-01	Abbott Laboratories	Processes to make apoptosis promoters
CN102477033A (zh) *	2010-11-23	2012-05-30	苏州波锐生物医药科技有限公司	苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
JP5886873B2 (ja)	2010-12-24	2016-03-16	メルク・シャープ・エンド・ドーム・ベー・フェー	Ｎ置換アゼチジン誘導体
EP3360870A1 (fr)	2013-02-19	2018-08-15	Novartis AG	Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des estrogènes

2014
- 2014-02-12 EP EP18156411.3A patent/EP3360870A1/fr not_active Withdrawn
- 2014-02-12 LT LTEP14708992.4T patent/LT2958907T/lt unknown
- 2014-02-12 GE GEAP201413917A patent/GEP201706638B/en unknown
- 2014-02-12 EP EP14708992.4A patent/EP2958907B1/fr active Active
- 2014-02-12 PT PT147089924T patent/PT2958907T/pt unknown
- 2014-02-12 MX MX2015010752A patent/MX359471B/es active IP Right Grant
- 2014-02-12 TR TR2018/06882T patent/TR201806882T4/tr unknown
- 2014-02-12 CN CN201480009342.8A patent/CN105008343B/zh active Active
- 2014-02-12 SI SI201430679T patent/SI2958907T1/en unknown
- 2014-02-12 HU HUE14708992A patent/HUE039052T2/hu unknown
- 2014-02-12 NZ NZ710385A patent/NZ710385A/en not_active IP Right Cessation
- 2014-02-12 BR BR112015018882-6A patent/BR112015018882B1/pt not_active IP Right Cessation
- 2014-02-12 CU CUP2015000090A patent/CU24337B1/es unknown
- 2014-02-12 MY MYPI2015702659A patent/MY174888A/en unknown
- 2014-02-12 PL PL14708992T patent/PL2958907T3/pl unknown
- 2014-02-12 SG SG11201505697VA patent/SG11201505697VA/en unknown
- 2014-02-12 KR KR1020157025506A patent/KR102279999B1/ko not_active Expired - Fee Related
- 2014-02-12 US US14/178,652 patent/US8877801B2/en active Active
- 2014-02-12 RS RS20180412A patent/RS57106B1/sr unknown
- 2014-02-12 PE PE2015001768A patent/PE20151428A1/es unknown
- 2014-02-12 CA CA2899030A patent/CA2899030C/fr active Active
- 2014-02-12 ME MEP-2018-102A patent/ME03061B/fr unknown
- 2014-02-12 HR HRP20180816TT patent/HRP20180816T1/hr unknown
- 2014-02-12 JP JP2015558090A patent/JP6364028B2/ja active Active
- 2014-02-12 WO PCT/US2014/015938 patent/WO2014130310A1/fr not_active Ceased
- 2014-02-12 AP AP2015008618A patent/AP2015008618A0/xx unknown
- 2014-02-12 US US14/768,341 patent/US9321746B2/en active Active
- 2014-02-12 DK DK14708992.4T patent/DK2958907T3/en active
- 2014-02-12 MA MA38325A patent/MA38325B1/fr unknown
- 2014-02-12 EA EA201591537A patent/EA028032B1/ru not_active IP Right Cessation
- 2014-02-12 AU AU2014219283A patent/AU2014219283C1/en not_active Ceased
- 2014-02-12 ES ES14708992.4T patent/ES2671516T3/es active Active
- 2014-02-18 UY UY0001035334A patent/UY35334A/es not_active Application Discontinuation
- 2014-02-18 JO JOP/2014/0038A patent/JO3494B1/ar active
- 2014-02-18 TW TW103105338A patent/TWI612040B/zh not_active IP Right Cessation
- 2014-02-19 AR ARP140100517A patent/AR094704A1/es unknown
- 2014-10-06 NO NO14795784A patent/NO3077717T3/no unknown
2015
- 2015-07-21 ZA ZA2015/05305A patent/ZA201505305B/en unknown
- 2015-07-23 IL IL240131A patent/IL240131B/en active IP Right Grant
- 2015-07-27 CL CL2015002098A patent/CL2015002098A1/es unknown
- 2015-07-31 TN TN2015000323A patent/TN2015000323A1/en unknown
- 2015-08-13 NI NI201500106A patent/NI201500106A/es unknown
- 2015-08-19 DO DO2015000202A patent/DOP2015000202A/es unknown
- 2015-08-19 PH PH12015501832A patent/PH12015501832B1/en unknown
- 2015-08-19 GT GT201500233A patent/GT201500233A/es unknown
- 2015-08-19 CR CR20150424A patent/CR20150424A/es unknown
2016
- 2016-03-10 US US15/066,425 patent/US9561211B2/en active Active
2017
- 2017-01-05 US US15/399,562 patent/US9931317B2/en active Active
2018
- 2018-02-17 US US15/898,561 patent/US10058534B2/en active Active
- 2018-04-27 CY CY20181100447T patent/CY1120155T1/el unknown
- 2018-08-17 HK HK18110605.6A patent/HK1251227A1/en unknown

Also Published As

Publication number	Publication date
US20150361065A1 (en)	2015-12-17
IL240131B (en)	2018-11-29
US9931317B2 (en)	2018-04-03
CR20150424A (es)	2015-10-19
MA38325A3 (fr)	2018-05-31
DK2958907T3 (en)	2018-06-06
NZ710385A (en)	2016-10-28
TW201443034A (zh)	2014-11-16
CA2899030A1 (fr)	2014-08-28
MX359471B (es)	2018-09-28
CN105008343A (zh)	2015-10-28
SI2958907T1 (en)	2018-05-31
MA38325B1 (fr)	2019-03-29
ME03061B (fr)	2019-01-20
NO3077717T3 (fr)	2018-07-21
PE20151428A1 (es)	2015-09-24
SG11201505697VA (en)	2015-09-29
US9561211B2 (en)	2017-02-07
EP2958907B1 (fr)	2018-02-28
CU24337B1 (es)	2018-04-03
JP6364028B2 (ja)	2018-07-25
UY35334A (es)	2014-09-30
US8877801B2 (en)	2014-11-04
AU2014219283B2 (en)	2015-10-29
AP2015008618A0 (en)	2015-07-31
PH12015501832A1 (en)	2015-11-09
WO2014130310A1 (fr)	2014-08-28
EP3360870A1 (fr)	2018-08-15
US20140235660A1 (en)	2014-08-21
AU2014219283A1 (en)	2015-08-13
PL2958907T3 (pl)	2018-07-31
CL2015002098A1 (es)	2015-11-13
KR102279999B1 (ko)	2021-07-22
PH12015501832B1 (en)	2015-11-09
TN2015000323A1 (en)	2017-01-03
CN105008343B (zh)	2017-12-08
NI201500106A (es)	2015-10-20
ES2671516T3 (es)	2018-06-06
US10058534B2 (en)	2018-08-28
RS57106B1 (sr)	2018-06-29
BR112015018882B1 (pt)	2021-09-14
MA38325A2 (fr)	2016-12-30
AU2014219283C1 (en)	2016-10-27
US20170112805A1 (en)	2017-04-27
CA2899030C (fr)	2021-03-09
GT201500233A (es)	2016-01-21
JP2016509022A (ja)	2016-03-24
BR112015018882A2 (pt)	2017-07-18
HK1211941A1 (en)	2016-06-03
IL240131A0 (en)	2015-09-24
CU20150090A7 (es)	2016-04-25
CY1120155T1 (el)	2018-12-12
ZA201505305B (en)	2016-09-28
MY174888A (en)	2020-05-20
US9321746B2 (en)	2016-04-26
TWI612040B (zh)	2018-01-21
EA201591537A1 (ru)	2015-12-30
GEP201706638B (en)	2017-03-10
HUE039052T2 (hu)	2018-12-28
DOP2015000202A (es)	2015-11-30
KR20150119385A (ko)	2015-10-23
JO3494B1 (ar)	2020-07-05
HK1251227A1 (en)	2019-01-25
EP2958907A1 (fr)	2015-12-30
LT2958907T (lt)	2018-04-25
PT2958907T (pt)	2018-03-23
AR094704A1 (es)	2015-08-19
US20180169063A1 (en)	2018-06-21
EA028032B1 (ru)	2017-09-29
HRP20180816T1 (hr)	2018-06-29
US20160184265A1 (en)	2016-06-30
MX2015010752A (es)	2015-11-30

Publication	Publication Date	Title
TR201806882T4 (tr)	2018-06-21	Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri.
US10774065B2 (en)	2020-09-15	1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JP6473457B2 (ja)	2019-02-20	Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
WO2015092634A1 (fr)	2015-06-25	Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes
EA031573B1 (ru)	2019-01-31	N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
JP6918378B2 (ja)	2021-08-11	ＣａＭＫＩＩ阻害剤及びその使用
JP2019509313A (ja)	2019-04-04	抗増殖剤としてのｄｄｘ３阻害剤の使用
HK1211941B (en)	2018-07-27	Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders